Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude CRT trial

This article was originally published in The Gray Sheet

Executive Summary

The first patient has been enrolled in the firm's 218-patient, randomized, double-blind RETHINQ trial. The study is evaluating cardiac resynchronization therapy in patients with NYHA Class III heart failure, narrow QRS complex and evidence of uncoordinated contraction of the lower chambers of the heart. CRT devices are currently indicated for patients with low ejection fraction and a wide QRS complex. By measuring dyssynchrony directly with Doppler or echocardiographic imaging, physicians may be able to better predict which patients will benefit from CRT, according to St. Jude. Patients randomized to receive CRT in RETHINQ will be treated with either a St. Jude Epic HF or Atlas HF CRT device...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT022590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel